CCAT2 and breast carcinoma: For the translational application of CCAT2 to treat breast cancer patients in the future, a drug or gene delivery system to specific subcellular compartments will be required to enrich CCAT2 in the cytoplasm, knockdown CCAT2 in the nucleus, or induce translocation of CCAT2 from nucleus to cytoplasm, thereby playing tumor-suppressing roles as a therapeutic target.